TPSTTempest Therapeutics, Inc.

Nasdaq tempesttx.com


$ 3.53 $ 0.06 (1.72 %)    

Friday, 26-Apr-2024 15:59:29 EDT
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 3.54
$ 3.56
$ 0.00 x 0
$ 0.00 x 0
$ 3.46 - $ 3.57
$ 0.17 - $ 9.77
402,988
na
54.57M
$ 1.38
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-19-2024 12-31-2023 10-K
2 11-08-2023 09-30-2023 10-Q
3 08-10-2023 06-30-2023 10-Q
4 05-10-2023 03-31-2023 10-Q
5 03-22-2023 12-31-2022 10-K
6 11-08-2022 09-30-2022 10-Q
7 08-15-2022 06-30-2022 10-Q
8 05-13-2022 03-31-2022 10-Q
9 03-29-2022 12-31-2021 10-K
10 11-10-2021 09-30-2021 10-Q
11 08-12-2021 06-30-2021 10-Q
12 05-13-2021 03-31-2021 10-Q
13 03-29-2021 12-31-2020 10-K
14 11-09-2020 09-30-2020 10-Q
15 08-10-2020 06-30-2020 10-Q
16 05-08-2020 03-31-2020 10-Q
17 03-11-2020 12-31-2019 10-K
18 11-13-2019 09-30-2019 10-Q
19 08-12-2019 06-30-2019 10-Q
20 05-15-2019 03-31-2019 10-Q
21 04-01-2019 12-31-2018 10-K
22 11-09-2018 09-30-2018 10-Q
23 08-09-2018 06-30-2018 10-Q
24 05-03-2018 03-31-2018 10-Q
25 03-15-2018 12-31-2017 10-K
26 11-02-2017 09-30-2017 10-Q
27 08-03-2017 06-30-2017 10-Q
28 05-09-2017 03-31-2017 10-Q
29 03-02-2017 12-31-2016 10-K
30 11-03-2016 09-30-2016 10-Q
31 08-04-2016 06-30-2016 10-Q
32 05-05-2016 03-31-2016 10-Q
33 02-26-2016 12-31-2015 10-K
34 11-05-2015 09-30-2015 10-Q
35 08-10-2015 06-30-2015 10-Q
36 05-11-2015 03-31-2015 10-Q
37 03-16-2015 12-31-2014 10-K
38 11-10-2014 09-30-2014 10-Q
39 08-07-2014 06-30-2014 10-Q
40 05-08-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 why-byrna-technologies-shares-are-trading-higher-by-around-7-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of Byrna Technologies Inc. (NASDAQ: BYRN) rose sharply during Friday’s session after the company reported better-than-ex...

 tempest-announces-publication-of-data-from-phase-1-trial-of-tpst-1120-in-patients-with-advanced-solid-tumors-in-journal-of-cancer-research-communications

TPST-1120, a first-in-class, oral, selective PPAR⍺ antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and ...

 hc-wainwright--co-reiterates-buy-on-tempest-therapeutics-maintains-47-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Tempest Therapeutics (NASDAQ:TPST) with a Buy and maintains $47 ...

 tempest-fy23-eps-191-vs-309-yoy-ended-the-year-with-392m-in-cash-and-cash-equivalents

Financial Results Year End 2023 Tempest ended the year with $39.2 million in cash and cash equivalents, compared to $31.2 m...

 scotiabank-initiates-coverage-on-tempest-therapeutics-with-sector-outperform-rating-announces-price-target-of-13

Scotiabank analyst George Farmer initiates coverage on Tempest Therapeutics (NASDAQ:TPST) with a Sector Outperform rating an...

 scotiabank-initiates-coverage-on-tempest-therapeutics-with-sector-outperform-rating-announces-price-target-of-13

Scotiabank analyst George Farmer initiates coverage on Tempest Therapeutics (NASDAQ:TPST) with a Sector Outperform rating an...

 hc-wainwright--co-maintains-buy-on-tempest-therapeutics-maintains-47-price-target

HC Wainwright & Co. analyst Joseph Pantginis maintains Tempest Therapeutics (NASDAQ:TPST) with a Buy and maintains $47 p...

 tempest-presents-new-data-at-the-sitc-2024-spring-scientific-meeting-supporting-potent-anti-tumor-activity-of-tpst-1120-in-multiple-cancer-types

Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune...

 jefferies-initiates-coverage-on-tempest-therapeutics-with-buy-rating-announces-price-target-of-15

Jefferies analyst Maury Raycroft initiates coverage on Tempest Therapeutics (NASDAQ:TPST) with a Buy rating and announces Pr...

 tempest-therapeutics-shares-up-19-premarket-a-press-release-earlier-announced-a-presentation-on-its-liver-cancer-treatment-at-asco-annual-meeting-2024

Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics...

 why-amc-entertainment-shares-are-trading-lower-by-around-14-here-are-other-stocks-moving-in-thursdays-mid-day-session

Gainers Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares climbed 83.5% to $0.4169 after reporting first-quarter results.

 crude-oil-rises-over-1-tapestry-posts-upbeat-earnings

U.S. stocks traded slightly higher midway through trading, with the Nasdaq Composite gaining around 50 points on Thursday. The...

 biggest-short-squeeze-stocks-of-the-week-two-biotech-stocks-move-up-to-top-the-list

Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a focus of traders looking for the ne...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION